Cuorips

Cuorips Equity

The The Equity of Cuorips (4894.T) as of Oct 16, 2026 is 4.75 B JPY. In the previous year, The Equity was 5.53 B JPY — a change of -14.05% (lower).

Equity

4.75 BJPY

YoY

-14.05%

Last updated:

In 2026, Cuorips's equity was 4.75 B JPY, a -14.05% increase from the 5.53 B JPY equity in the previous year.

The Cuorips Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2021
4.22 B JPY
Jan 1, 2022
3.90 B JPY
Jan 1, 2023
3.45 B JPY
Jan 1, 2024
5.98 B JPY
Jan 1, 2025
5.53 B JPY
Jan 1, 2026
4.75 B JPY
The Cuorips Equity history
YEAREquityYoY
4.75 BJPY-14.05%
5.53 BJPY-7.61%
5.98 BJPY+73.22%
3.45 BJPY-11.34%
3.90 BJPY-7.74%
4.22 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cuorips Stock analysis

What does Cuorips do? Cuorips Inc is a Japanese company operating in the Health Care sector, specifically within Biotechnology. Headquartered in Chuo-Ku, Tokyo, the company focuses on the development and commercialization of regenerative medical products, with a particular emphasis on human iPS cell-derived cardiomyocyte sheets. Cuorips also engages in a contract development and manufacturing organization (CDMO) business, utilizing its CLiC-1 facility, a commercial cell culture and processing center designed according to the company's original concept. The company has 46 full-time employees and completed its initial public offering (IPO) on June 27, 2023. Cuorips collaborates with universities, research institutions, and major pharmaceutical companies for in-house research and joint research initiatives. Its primary product, human iPS cell-derived cardiomyocyte sheets, is targeted at regenerative medical applications for the heart and other areas. The company's website is https://cuorips.co.jp/. Cuorips is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cuorips's Equity

Cuorips's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cuorips's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cuorips's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cuorips's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cuorips’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cuorips stock

The Equity of Cuorips is 4.75 B JPY in 2026.

The Equity of Cuorips changed from 5.53 B JPY to 4.75 B JPY, representing a -14.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Cuorips since 2006 – with annual values, charts, and detailed analysis.

The Equity's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Cuorips historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cuorips

All Key Metrics — Cuorips